Danish healthcare company Novo Nordisk A/S (NVO) announced Friday that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for insulin aspart injection Fiasp 100 u/mL, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes.
from RTT - Biotech https://ift.tt/2tJSRt2
via IFTTT
No comments:
Post a Comment